iwCLL 2013: Dr. Jeff Sharman Outlines Options if You Need Treatment NOW
In Part 5 of my interview from iwCLL 2013, Dr. Jeff Sharman outlines what factors go into deciding how to manage our disease NOW with these new drugs coming, but not here yet.
He lists many of the available trials for both treatment naive and relapsed refractory patients, focusing mostly on the two leading oral CLL drugs, idelalisib and ibrutinib.
As always your best source of finding out about the latest on the status of any clinical trials is visiting clinical trials.gov and don't be afraid to email the trial co-ordinator if you have questions. They want to hear from us. That's how they fill their trials. It is a very user friendly web site and should be part of your life.
There are some great options out there, and we need to know more. Our work is not done. We are not cured with any of these therapies. There are relapses late and early.
We need more clinical research to tell us what works best and most safely, but without us patients enrolling, all research halts. No doubt the lightning fast FDA approval of ibrutinib, going from test tube to prescription pad in under 8 years, was facilitated by the dazzling rapidity of accrual in many of the important trials.
Please carefully consider investigating some of the promising trials of combination therapies with the better known novel agents or one of the newer less studied but very promising novel agents such as ABT-199 and IPI-145 or ONO-4059 and others.
Here is Dr. Sharman. If you haven't seen Parts 1-4 please scroll down or search under Dr. Sharman on my blog.
Part 6 and 7 are on their way.
And so are my interviews with Drs. Kay, Byrd, Kipps, Pagel and Hallek.
On a personal note, I am a touch sick again or still: a deep chesty cough and fatigue. We will see what the morning brings. If I am not better, time to break out for my "just in case" antibiotic.
He lists many of the available trials for both treatment naive and relapsed refractory patients, focusing mostly on the two leading oral CLL drugs, idelalisib and ibrutinib.
As always your best source of finding out about the latest on the status of any clinical trials is visiting clinical trials.gov and don't be afraid to email the trial co-ordinator if you have questions. They want to hear from us. That's how they fill their trials. It is a very user friendly web site and should be part of your life.
There are some great options out there, and we need to know more. Our work is not done. We are not cured with any of these therapies. There are relapses late and early.
We need more clinical research to tell us what works best and most safely, but without us patients enrolling, all research halts. No doubt the lightning fast FDA approval of ibrutinib, going from test tube to prescription pad in under 8 years, was facilitated by the dazzling rapidity of accrual in many of the important trials.
Please carefully consider investigating some of the promising trials of combination therapies with the better known novel agents or one of the newer less studied but very promising novel agents such as ABT-199 and IPI-145 or ONO-4059 and others.
Here is Dr. Sharman. If you haven't seen Parts 1-4 please scroll down or search under Dr. Sharman on my blog.
Part 6 and 7 are on their way.
And so are my interviews with Drs. Kay, Byrd, Kipps, Pagel and Hallek.
On a personal note, I am a touch sick again or still: a deep chesty cough and fatigue. We will see what the morning brings. If I am not better, time to break out for my "just in case" antibiotic.
Labels: ABT-199, Chronic lymphocytic leukemia, Clinical trials, CLL, decisions, Dr. Sharman, ibrutinib, Idelalisib, interviews, IPI-145, iwCLL 2013, off label, ONO-4059, Video
posted by Brian Koffman at
12:24 AM
2 Comments:
That's the question I would ask Dr Sharman if I could! Thanks Brian.
Thank you for these videos. So much to learn! Take care, and I hope you are feeling much better soon.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home